Roivant Sciences Surges 15% to 52-Week High After Experimental Drug Achieves Perfect Response Rate in Landmark Trial
Roivant Sciences stock surges 15% to a 52-week high after brepocitinib achieves a perfect 100% response rate in a Phase 2 trial for cutaneous sarcoidosis, a rare and debilitating skin disease.